试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-21
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
编号:NCT03498716登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Atezolizumab、Paclitaxel、Dose-dense Doxorubicin or dose-dense Epirubicin、Cyclophosphamide
登记的停止原因(原文):The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
编号:NCT00819169登记状态:提前终止企业 / 申办者:NantCell, Inc.
药物 / 成分:AMG 479、AMG 655
登记的停止原因(原文):Sponsor decision - subjects rolled over to protocol 20101116
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Oral Anticoagulation in Haemodialysis Patients
编号:NCT02886962登记状态:提前终止企业 / 申办者:University Hospital, Strasbourg, France
药物 / 成分:No oral anticoagulation、Oral anticoagulation with vitamin K antagonists
登记的停止原因(原文):not enough patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Hydroxychloroquine and Cognitive Function After Surgery
编号:NCT03025087登记状态:提前终止企业 / 申办者:Duke University
药物 / 成分:Hydroxychloroquine
登记的停止原因(原文):Showed no benefit
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial
编号:NCT03259165登记状态:提前终止企业 / 申办者:Indiana University
药物 / 成分:Nitrates、Loop Diuretics
登记的停止原因(原文):COVID-19 pandemic. Initially had planned to resume study, but ultimately decided to close.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Effect of Azithromycin on Failure Proportion of Severe Periodontitis Non-surgical Treatment
编号:NCT04198649登记状态:提前终止企业 / 申办者:University Hospital, Strasbourg, France
药物 / 成分:Non-surgical periodontal treatment and azithromycin treatment、Non-surgical periodontal treatment and placebo treatment
登记的停止原因(原文):not enough patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
编号:NCT04377087登记状态:提前终止企业 / 申办者:Sarah E Taylor
药物 / 成分:Olaparib
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Evaluation of ADG20 for the Prevention of COVID-19
编号:NCT04859517登记状态:提前终止企业 / 申办者:Invivyd, Inc.
药物 / 成分:ADG20、Placebo
登记的停止原因(原文):All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
编号:NCT05223673登记状态:提前终止企业 / 申办者:Institut de Recherches Internationales Servier
药物 / 成分:Futuximab/modotuximab、Trifluridine/Tipiracil、Trifluridine/Tipiracil
登记的停止原因(原文):Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not started due to strategic reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-20
Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial
编号:NCT05293106登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Platelet Transfusion
登记的停止原因(原文):Difficulty recruiting and enrolling subjects.
查看官方原始记录 ↗